Michael Grimm

Company: Regor Therapeutics

Job title: Head of Metabolic Diseases

Seminars:

GLP1R Small Molecule Agonists Could Make a Meaningful Difference for Patients 2:00 pm

Examining the need for differentiated products as more GLP-1s are being developed Developing small molecule GLP1R agonists to meet the specific needs of the patients Exploring the opportunities for combinations of agonists to gain long-term health benefitsRead more

day: Conference Day Two

Panel Discussion: Exploring the Weight Independent Benefits of GLP-1 3:00 pm

Evaluating the impact of GLP-1s: are all observed benefits attributable to weight reduction or are other mechanisms in play? Considering how co-morbidities should be addressed from a clinical and commercial strategy perspective Clarifying uncertainties related to expanding into numerous new therapeutic areasRead more

day: Conference Day One